Veru Inc (NASDAQ:VERU) Sellers Rose By 23.22% Their Shorts As Of May 3, 2018

May 3, 2018 - By Alice Reed

Veru Inc (NASDAQ:VERU) had an increase of its shares shorted by 23.22%. FINRA announced shares shorted of VERU’s total 316,300 shares. The 256,700 previous shares are up with 23.22%. With Average volume 292,400, VERU’s previous position will take 1 days to recover. Float short on Veru Inc is 1.12%.

VERU is reaching $1.9263 during the last trading session, after increased 1.92%.Currently Veru Inc. is uptrending after 64.49% change in last May 3, 2017. VERU has 63,061 shares volume. VERU outperformed the S&P500 by 52.94%.

Veru Inc., a medical therapeutics company, develops, makes, and markets consumer health care products.The company has $103.08 million market cap. The companyÂ’s pharmaceuticals product portfolio includes Tamsulosin delayed release sachet that is under bioequivalence study for the treatment of benign prostatic hyperplasia; MSS-722, a fixed ratio of trans- and cis-clomiphene citrate isomers, which is under the Phase II clinical trial to treat male infertility caused by testicular dysfunction; APP-944, a zuclomiphene citrate that is under the Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and APP-111, an oral tubulin targeting chemotherapy, which is under the preclinical study to treat metastatic prostate, breast, and ovarian cancers, as well as APP-111/112 oral agents that target colchicine binding site of tubulin for the treatment of gout and familial mediterranean fever.Last it reported negative earnings. It also provides consumer health and medical devices, including PREBOOST benzocaine wipes for premature ejaculation; and FC2, which is female disposable contraceptive device, as well as FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus.

Veru Inc. (NASDAQ:VERU) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.